Trial Profile
A Phase 2 Trial of MLN0264 in Previously Treated Patients With Advanced or Metastatic Pancreatic Adenocarcinoma Expressing Guanylyl Cyclase C (GCC)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 13 Apr 2022
Price :
$35
*
At a glance
- Drugs Indusatumab vedotin (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Sponsors Takeda Oncology
- 10 Apr 2022 This trial has been completed in Italy (End Date: 15 Jan 2015), according to European Clinical Trials Database record.
- 19 May 2017 Results published in the Investigational New Drugs
- 06 Apr 2017 Status changed from active, no longer recruiting to discontinued due to Business Decision.